Meanwhile, TLR4 agonists in combination with programmed death ligand 1 (PD-L1) blockers significantly improved the anti-tumor effect, providing a new strategy and experimental basis for combined tumor immunotherapy (Traini et al., 2019). Here, TLR4 is linked to neoplasm.